Analysis of 314,618 adults aged 70+ in England reveals that live shingles vaccination (Zostavax) reduced all-cause mortality by 36%, all-cause hospitalizations by 17%, and infection-related hospitalizations by 19-25% compared to unvaccinated peers. These protective effects persisted for at least five years, suggesting the vaccine provides health benefits far beyond its intended shingles prevention. This finding adds to emerging evidence of 'non-specific vaccine effects' — where live vaccines appear to broadly enhance immune function and reduce death from various causes. The magnitude of protection rivals that seen with major medical interventions, potentially making shingles vaccination one of the most impactful health measures for older adults. However, this observational study cannot prove causation, and residual confounding remains possible despite sophisticated statistical adjustments. The research examined a specific live vaccine formulation; newer recombinant shingles vaccines may not show similar effects. As this preprint awaits peer review, these striking results require validation in randomized controlled trials before reshaping vaccination policies. If confirmed, the findings could transform how we view vaccination's role in healthy aging.